Intravesical drug delivery: Challenges, current status, opportunities and novel strategies

Journal of Controlled Release

Volumn 148, Issue 2, 2010, Pages 147-159

  GuhaSarkar, Shruti ^a   Banerjee, R ^a  

^a INDIAN INSTITUTE OF TECHNOLOGY BOMBAY   (India)

Author keywords

In situ gels; Intravesical drug delivery; Mucoadhesive polymers; Nanoparticles; Urinary bladder

Indexed keywords

ANATOMICAL FEATURES; BARRIER FUNCTIONS; BLADDER WALL; CHEMICAL INTERACTIONS; CHEMICAL MOLECULES; CURRENT STATUS; DIMETHYL SULPHOXIDES; DRUG CARRIER; DRUG CONCENTRATION; DRUG SOLUTIONS; ENCAPSULATED NANOPARTICLES; FUTURE PROSPECTS; GELATIN NANOPARTICLES; IN SITU GELS; IN-SITU; IN-SITU-GELLING; INTRAVESICAL DRUG DELIVERY; MAGNETIC PARTICLE; MUCOADHESIVE POLYMERS; NANOCARRIERS; NOVEL STRATEGIES; PERMEATION ENHANCERS; POLYMERIC HYDROGELS; POLYMERIC NANOPARTICLES; RESIDENCE TIME; SYSTEMIC ADMINISTRATION; TARGET SITES; TEMPERATURE SENSITIVE; TIGHT JUNCTIONS; TIME SPAN; TOXIC SUBSTANCES; URINARY BLADDER; UROTHELIAL CELLS; UROTHELIUM;

BODY FLUIDS; DRUG DELIVERY; DRUG PRODUCTS; ELECTROMOTIVE FORCE; HYDROGELS; LIPOSOMES; NANOMAGNETICS; NANOPARTICLES; PHOSPHOLIPIDS; POLYMERS; SULFUR COMPOUNDS;

DRUG INTERACTIONS;

BIOMATERIAL; CHITOSAN; CISPLATIN; DENDRIMER; DIMETHYL SULFOXIDE; DOXORUBICIN; DRUG CARRIER; EPIRUBICIN; GELATIN; GEMCITABINE; LIPOSOME; MITOMYCIN C; NANOPARTICLE; PACLITAXEL; POLYMER; THIOTEPA;

BIODEGRADABILITY; BLADDER CANCER; DIFFUSION; DRUG DELIVERY SYSTEM; FORCE; HUMAN; HYDROGEL; INTERSTITIAL CYSTITIS; MICTURITION; MOLECULE; NANOENCAPSULATION; NANOTECHNOLOGY; NONHUMAN; PRIORITY JOURNAL; REVIEW; TEMPERATURE; UROTHELIUM;

ADHESIVENESS; ADMINISTRATION, INTRAVESICAL; ANIMALS; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; DRUG COMPOUNDING; HUMANS; NANOPARTICLES; PERMEABILITY; PHARMACEUTICAL PREPARATIONS; POLYMERS; URINARY BLADDER; URINARY BLADDER DISEASES; UROTHELIUM;

EID: 78649320557     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2010.08.031     Document Type: Review

References (115)

1. Lewis S.A. Everything you wanted to know about the bladder epithelium but were afraid to ask. Am. J. Physiol. Renal Physiol. 2000, 278:867-874.
2. Tyagi P., Wu P.C., Chancellor M., Yoshimura N., Huang L. Recent advances in intravesical drug/gene delivery. Mol. Pharm. 2006, 3(4):369-379.
3. Giannantoni A., Di Stasi S.M., Chancellor M.B., Costantini E., Porena M. New frontiers in intravesical therapies and drug delivery. Eur. Urol. 2006, 50:1183-1193.
4. Lewis S.A. The mammalian urinary bladder: it's more than accommodating. News Physiol. Sci. 1986, 1:61-65.
5. Kong X.T., Deng F.M., Hu P., Liang F.X., Zhou G., Auerbach A.B., Genieser N., Nelson P.K., Robbins E.S., Shapiro E., Kachar B., Sun T.T. Roles of uroplakins in plaque formation, umbrella cell enlargement and urinary tract diseases. J. Cell Biol. 2004, 167(6):1195-1204.
6. Wu X.R., Lin J.H., Walz T., Haner M., Yu J., Aebi U., Sun T.T. Mammalian uroplakins: a group of highly conserved urothelial differentiation-related membrane proteins. J. Biol. Chem. 1994, 269(18):13716-13724.
7. Yu J., Lin J.-H., Wu X.-R., Sun T.-T. Uroplakins Ia and Ib, two major differentiation products of bladder epithelium, belong to a family of four transmembrane domain (4TM) proteins. J. Cell Biol. 1994, 125:171-182.
8. Soler R., Bruschini H., Martins J.R., Dreyfuss J.L., Camara N.O., Alves M.T., Leite K.R., Truzzi J.C., Nader H.B., Srougi M., Ortiz V. Urinary glycosaminoglycans as biomarker for urothelial injury: is it possible to discriminate damage from recovery?. Urology 2008, 72:937-942.
9. Poggi M.M., Johnstone P.A.S., Conner R.J. Glycosaminoglycan content of human bladders: a method of analysis using cold-cup biopsies. Urol. Oncol. 2000, 5:234-237.
10. Birder L.A., De Groat W.C. Mechanisms of disease: involvement of the urothelium in bladder dysfunction. Nat. Clin. Pract. Urol. 2007, 4(1):46-54.
11. Birder L.A. More than just a barrier: urothelium as a drug target for urinary bladder pain. Am. J. Physiol. Renal Physiol. 2005, 289:F489-F495.
12. Kaufman D.S., Shipley W.U., Feldman A.S. Bladder cancer. Lancet 2009, 374:239-249.
13. Kirkali Z., Chan T., Manoharan M., Algaba F., Busch C., Cheng L., Kiemeney L., Kriegmair M., Montironi R., Murphy W.M., Sesterhenn I.A., Tachibana M., Weider J. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 2005, 66(6 Suppl. 1):4-34.
14. Richie J.P., Bono A., Denis L.J., Jewett M.A.S., Kakizoe T., Kotake T., Shirai T., ten Kate F.J.W. Tumor, nodes, metastasis (TNM) classification of bladder cancer. Urol. Oncol. 1998, 4(4-5):90-93.
15. Colombel M., Soloway M., Akaza H., Bohle A., Palou J., Buckley R., Lamm D., Brausi M., Witjes J.A., Persad R. Epidemiology, staging, grading, and risk stratification of bladder cancer. Eur. Urol. Suppl. 2008, 7:618-626.
16. Grasso M. Bladder cancer: a major public health issue. Eur. Urol. Suppl. 2008, 7:510-515.
17. Kaufman D.S. Challenges in the treatment of bladder cancer. Ann. Oncol. 2006, 17(Suppl. 5):v106-v112.
18. Oosterlinck W., Lobel B., Jakse G., Malmström P.U., Stöckle M., Sternberg C. The EAU Working Group on Oncological Urology, Guidelines on Bladder Cancer. Eur. Urol. 2002, 41(2):105-112.
19. Konety B.R., Joyce G.F., Wise M. Chapter 7: Bladder and Upper Tract Urothelial Cancer 2007, 225-283. US Government Printing Office, Washington DC, (NIH Publication No. 07-5512). M.S. Litwin, C.S. Saigal (Eds.).
20. Katz G., Hackett R.L., Wajsman Z. Bladder wall fibrosis following intravesical mitomycin treatment for superficial bladder cancer. Urology 1996, 47(6):928-929.
21. Evans C.P., Debruyne F.M.J., Payne H., Solsona E., Teillac P., Tubaro A. Bladder cancer: management and future directions. Eur. Urol. Suppl. 2007, 6(3):365-373.
22. Davidsson T., Wullt B., Könyves J., Månsson A., Månsson W. Urinary diversion and bladder substitution in patients with bladder cancer. Urol. Oncol. 2000, 5(5):224-231.
23. Koya M.P., Simon M.A., Soloway M.S. Complications of intravesical therapy for urothelial cancer of the bladder. J. Urol. 2006, 175(6):2004-2010.
24. Chancellor M.B., Yoshimura N. Treatment of interstitial cystitis. Urology 2004, 63(Suppl. 3A):85-92.
25. Dasgupta J., Tincello D.G. Interstitial cystitis/bladder pain syndrome: an update. Maturitas 2009, 64(4):212-217.
26. Kurth K.H., Parsons C.L. The interstitial cystitis syndrome: intravesical and oral treatment. Eur. Urol. Suppl. 2003, 2:2-9.
27. Rosamilia A. Painful bladder syndrome/interstitial cystitis. Best Pract. Res. Clin. Obstet. Gynaecol. 2005, 19(6):843-859.
28. Karsenty G., AlTaweel W., Hajebrahimi S., Corcos J. Efficacy of Interstitial Cystitis Treatments. A Review, EAU-EBU Update Series 2006, 4(2):47-61.
29. Hurst R.E., Moldwin R.M., Mulholland S.G. Bladder defense molecules, urothelial differentiation, urinary biomarkers and interstitial cystitis. Urology 2007, 69(Suppl. 4A):17-23.
30. Bhavanandan V.P., Erickson D.R., Herb N., Sheykhnazari M., Ordille S. Use of glycosaminoglycans in the treatment of interstitial cystitis: a strategy to improve efficacy. Int. Congr. Ser. 2001, 1223:227-237.
31. Hauser P.J., Buethe D.A., Califano J., Sofinowski T.M., Culkin D.J., Hurst R.E. Restoring barrier function to acid damaged bladder by intravesical chondroitin sulfate. J. Urol. 2009, 182(5):2477-2482.
32. Lazzeri M., Spinelli M., Beneforti P., Malaguti S., Giardiello G., Turini D. Intravesical infusion of resiniferatoxin by a temporary in situ drug delivery system to treat interstitial cystitis: a pilot study. Eur. Urol. 2004, 45(1):98-102.
33. Smith C.P. Botulinum toxin in the treatment of OAB, BPH, and IC. Toxicon 2009, 54(5):639-646.
34. Giannantoni A., Costantini E., Di Stasi S.M., Tascini M.C., Bini V., Porena M. Botulinum A toxin intravesical injections in the treatment of painful bladder syndrome: a pilot study. Eur. Urol. 2006, 49(4):704-709.
35. Lazzeri M., Beneforti P., Benaim G., Maggi C.A., Lecci A., Turini D. Intravesical capsaicin for treatment of severe bladder pain: a randomized placebo controlled study. J. Urol. 1996, 156(3):947-952.
36. Chancellor M.B., De Groat W.C. Intravesical capsaicin and resiniferatoxin therapy: spicing up the ways to treat the overactive bladder. J. Urol. 1999, 162(1):3-11.
37. Shen Z., Shen T., Wientjes M.G., O'Donnell M.A., Au J.L.S. Intravesical treatments of bladder cancer: review. Pharm. Res. 2008, 25(7):1500-1510.
38. Amling C.L. Diagnosis and management of superficial bladder cancer. Curr. Probl. Cancer 2001, 25(4):224-278.
39. Melekos M.D., Chionis H.S., Paranychianakis G.S., Dauher H.H. Intravesical 4'-epidoxorubicin (epirubicin) versus bacillus Calmette-Guerin: a controlled prospective study on the prophylaxis of superficial bladder cancer. Cancer 1993, 72:1749-1755.
40. Stricker P., Pryor K., Nicholson T., Goldstein D., Golovsky D., Ferguson R. BCG plus interferon alpha 2b in patients with superficial bladder cancer. Urology 1996, 48:957-962.
41. Malmström P.U. Intravesical therapy of superficial bladder cancer. Crit. Rev. Oncol. Hematol. 2003, 47(2):109-126.
42. Calabrò F., Sternberg C.N. Neoadjuvant and adjuvant chemotherapy in muscle-invasive bladder cancer. Eur. Urol. 2009, 55(2):348-358.
43. Vaughn D.J. Paclitaxel and carboplatin in bladder cancer: recent developments. Eur. J. Cancer 2000, 36(Suppl. 2):7-12.
44. Von der Maase H. Gemcitabine and cisplatin in locally advanced and/or metastatic bladder cancer. Eur. J. Cancer 2000, 36(Suppl. 2):13-16.
45. Gasión J.P.B., Cruz J.F.J. Improving efficacy of intravesical chemotherapy. Eur. Urol. 2006, 50(2):225-234.
46. Au J.L.S., Jang S.H., Wientjes M.G. Clinical aspects of drug delivery to tumors. J. Control. Release 2002, 78(1-3):81-95.
47. Kamat A.M., Lamm D.J. Intravesical therapy for bladder cancer. Urology 2000, 55(2):161-168.
48. Farokhzad O.C., Dimitrakov J.D., Karp J.M., Khademhosseini A., Freeman M.R., Langer R. Drug delivery systems in urology-getting "smarter". Urology 2006, 68:463-469.
49. Di Stasi S.M., Giannantoni A., Giurioli A., Valenti M., Zampa G., Storti L., Attisani F., Carolis A.D., Capelli G., Vespasiani G., Stephen R.L. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. Lancet Oncol. 2006, 7:43-51.
50. Negrete H.O., Lavelle J.P., Berg J., Lewis S.A., Zeidel M.L. Permeability properties of the intact mammalian bladder epithelium. Am. J. Physiol. Renal Fluid Electrolyte Physiol. 1996, 271:F886-F894.
51. Gommersall L., Shergill I.S., Ahmed H.U., Hayne D., Arya M., Patel H.R.H., Hashizume M., Gill I.S. Nanotechnology and its relevance to the urologist. Eur. Urol. 2007, 52(2):368-375.
52. Silva G.A. Introduction to nanotechnology and its applications to medicine. Surg. Neurol. 2004, 61(3):216-220.
53. Alexis F., Rhee J.W., Richie J.P., Radovic-Moreno A.F., Langer R., Farokhzad O.C. New frontiers in nanotechnology for cancer treatment. Urol. Oncol.: Seminars and Original Investigations 2008, 26(1):74-85.
54. Kim G.J., Nie S. Targeted cancer nanotherapy. Mater. Today 2005, 8(8, Suppl. 1):28-33.
55. Singh R., Lillard J.W. Nanoparticle-based targeted drug delivery. Exp. Mol. Pathol. 2009, 86(3):215-223.
56. Cho K., Wang X., Nie S., Chen Z., Shin D.M. Therapeutic nanoparticles for drug delivery in cancer. Clin. Cancer Res. 2008, 14(5):1310-1316.
57. Cortesi R., Nastruzzi C. Liposomes, micelles and microemulsions as new delivery systems for cytotoxic alkaloids. Pharm. Sci. Technolo. Today 1999, 2(7):288-298.
58. Malam Y., Loizidou M., Seifalian A.M. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharmacol. Sci. 2009, 30(11):592-599.
59. Fraser M.O., Chuang Y.C., Tyagi P., Yokoyama T., Yoshimura N., Huang L., De Groat W.C., Chancellor M.B. Intravesical liposome administration-a novel treatment for hyperactive bladder in the rat. Urology 2003, 61(3):656-663.
60. Tyagi P., Chancellor M.B., Li Z., De Groat W.C., Yoshimura N., Fraser M.O., Huang L. Urodynamic and immunohistochemical evaluation of intravesical capsaicin delivery using thermosensitive hydrogel and liposomes. J. Urol. 2004, 171:483-489.
61. Frangos D.N., Killion J.J., Fan D., Fishbeck R., von Eschenbach A.C., Fidler I.J. The development of liposomes containing interferon alpha for the intravesical therapy of human superficial bladder cancer. J. Urol. 1990, 143:1252-1256.
62. Chuang Y.C., Tyagi P., Huang C.C., Yoshimura N., Wu M., Kaufman J., Chancellor M.B. Urodynamic and immunohistochemical evaluation of intravesical botulinum toxin a delivery using liposomes. J. Urol. 2009, 182(2):786-792.
63. Pradhan P., Giri J., Rieken F., Koch C., Mykhaylyk O., Döblinger M., Banerjee R., Bahadur D., Plank C. Targeted temperature sensitive magnetic liposomes for thermo-chemotherapy. J. Control. Release 2010, 142(1):108-121.
64. Obata Y., Tajima S., Takeoka S. Evaluation of pH-responsive liposomes containing amino acid-based zwitterionic lipids for improving intracellular drug delivery in vitro and in vivo. J. Control. Release 2010, 142(2):267-276.
65. Wong H.L., Bendayan R., Rauth A.M., Li Y., Wu X.Y. Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles. Adv. Drug Deliv. Rev. 2007, 59(6):491-504.
66. Subedi R.K., Kanga K.W., Choi H.K. Preparation and characterization of solid lipid nanoparticles loaded with doxorubicin. Eur. J. Pharm. Sci. 2009, 37:508-513.
67. Reddy L.H., Sharma R.K., Chuttani K., Mishra A.K., Murthy R.S.R. Influence of administration route on tumor uptake and biodistribution of etoposide loaded solid lipid nanoparticles in Dalton's lymphoma tumor bearing mice. J. Control. Release 2005, 105:185-198.
68. Xu Z., Chen L., Gu W., Gao Y., Lin L., Zhang Z., Xi Y., Li Y. The performance of docetaxel-loaded solid lipid nanoparticles targeted to hepatocellular carcinoma. Biomaterials 2009, 30(2):226-232.
69. Reis C.P., Neufeld R.J., Ribeiro A.J., Veiga F. Nanoencapsulation II. Biomedical applications and current status of peptide and protein nanoparticulate delivery systems. Nanomedicine 2006, 2:53-65.
70. Lee C.H., Singla A., Lee Y. Biomedical applications of collagen. Int. J. Pharmaceut. 2001, 221:1-22.
71. Kratz F., Beyer U., Roth T., Tarasova N., Collery P., Lechenault F., Cazabat A., Schumacher P., Unger C., Falken U. Transferrin conjugates of doxorubicin: synthesis, characterization, cellular uptake, and in vitro efficacy. J. Pharm. Sci. 1998, 87:338-346.
72. Kratz F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J. Control. Release 2008, 132(3):171-183.
73. Lu Z., Yeh T.K., Tsai M., Au J.L.S., Wientjes M.G. Paclitaxel-loaded gelatin nanoparticles for intravesical bladder cancer therapy. Clin. Cancer Res. 2004, 10:7677-7684.
74. Chang L.C., Wu S.C., Tsai J.W., Yu T.J., Tsai T.R. Optimization of epirubicin nanoparticles using experimental design for enhanced intravesical drug delivery. Int. J. Pharm. 2009, 376:195-203.
75. Gaucher G., Marchessault R.H., Leroux J.C. Polyester-based micelles and nanoparticles for the parenteral delivery of taxanes. J. Control. Release 2010, 143(1):2-12.
76. Mattheolabakis G., Taoufik E., Haralambous S., Roberts M.L., Avgoustakis K. In vivo investigation of tolerance and antitumor activity of cisplatin-loaded PLGA-mPEG nanoparticles. Eur. J. Pharm. Biopharm. 2009, 71(2):190-195.
77. Kumari A., Yadav S.K., Yadav S.C. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf. B Biointerfaces 2010, 75(1):1-18.
78. Merdan T., Kopecek J., Kissel T. Prospects for cationic polymers in gene and oligonucleotide therapy against cancer. Adv. Drug Deliv. Rev. 2002, 54(5):715-758.
79. Duncan R., Izzo L. Dendrimer biocompatibility and toxicity. Adv. Drug Deliv. Rev. 2005, 57:2215-2237.
80. Svenson S. Dendrimers as versatile platform in drug delivery applications. Eur. J. Pharm. Biopharm. 2009, 71(3):445-462.
81. Esfand R., Tomalia D.A. Poly(amidoamine) PAMAM dendrimers: from biomimicry to drug delivery and biomedical applications. Drug Discov. Today 2001, 6:427-436.
82. Tang M.X., Redemann C.T., Szoka F.C. In vitro gene delivery by degraded polyamidoamine dendrimers. Bioconjug. Chem. 1996, 7:703-714.
83. Patri A.K., Myc A., Beals J., Thomas T.P., Bander N.H., Baker J.R. Synthesis and in vitro testing of J591 antibody-dendrimer conjugates for targeted prostate cancer therapy. Bioconjug. Chem. 2004, 15:1174-1181.
84. Wang Z.X., Itoh Y.S., Hosaka Y., Kobayashi I., Nakano Y., Maeda I., Umeda F., Yamakawa J., Nishimine M., Suenobu T., Fukuzumi S., Kawase M., Yagi K. Mechanism of enhancement effect of dendrimer on transdermal drug permeation through polyhydroxyalkanoate matrix. J. Biosci. Bioeng. 2003, 96:537-540.
85. Arruebo M., Fernández-Pacheco R., Ibarra M.R., Santamaría J. Magnetic nanoparticles for drug delivery. Nano Today 2007, 2(3):22-32.
86. Leakakos T., Ji C., Lawson G., Peterson C., Goodwin S. Intravesical administration of doxorubicin to swine bladder using magnetically targeted carriers. Cancer Chemother. Pharmacol. 2003, 51:445-450.
87. Chertok B., Moffat B.A., David A.E., Yu F., Bergemann C., Ross B.D., Yang V.C. Iron oxide nanoparticles as a drug delivery vehicle for MRI monitored magnetic targeting of brain tumors. Biomaterials 2008, 29(4):487-496.
88. Stern J.M., Cadeddu J.A. Emerging use of nanoparticles for the therapeutic ablation of urologic malignancies. Urol. Oncol.: Seminars and Original Investigations 2008, 26:93-96.
89. Gurunathan S., Lee K.J., Kalishwaralal K., Sheikpranbabu S., Vaidyanathan R., Eom S.H. Antiangiogenic properties of silver nanoparticles. Biomaterials 2009, 30(31):6341-6350.
90. Biju V., Mundayoor S., Omkumar R.V., Anas A., Ishikawa M. Bioconjugated quantum dots for cancer research: present status, prospects and remaining issues. Biotechnol. Adv. 2010, 28(2):199-213.
91. Tan A., Simovic S., Davey A.K., Rades T., Prestidge C.A. Silica-lipid hybrid (SLH) microcapsules: a novel oral delivery system for poorly soluble drugs. J. Control. Release 2009, 134(1):62-70.
92. Foldvari M., Bagonluri M. Carbon nanotubes as functional excipients for nanomedicines: II. Drug delivery and biocompatibility issues. Nanomedicine 2008, 4(3):183-200.
93. Zhang X., Meng L., Lu Q., Fei Z., Dyson P.J. Targeted delivery and controlled release of doxorubicin to cancer cells using modified single wall carbon nanotubes. Biomaterials 2009, 30(30):6041-6047.
94. Smart J.D. The basics and underlying mechanisms of mucoadhesion. Adv. Drug Deliv. Rev. 2005, 57(11):1556-1568.
95. Eroglu M., Irmak S., Acar A., Denkbas E.B. Design and evaluation of a mucoadhesive therapeutic agent delivery system for postoperative chemotherapy in superficial bladder cancer. Int. J. Pharm. 2002, 235:51-59.
96. Burjak M., Bogataj M., Velnar M., Grabnar I., Mrhar A. The study of drug release from microspheres adhered on pig vesical mucosa. Int. J. Pharm. 2001, 224:123-130.
97. Kerec M., Bogataj M., Verani P., Mrhar A. Permeability of pig urinary bladder wall: the effect of chitosan and the role of calcium. Eur. J. Pharm. Sci. 2005, 25:113-121.
98. Kerec Kos M., Bogataj M., Verani P., Mrhar A. Permeability of pig urinary bladder wall: time and concentration dependent effect of chitosan. Biol. Pharm. Bull. 2006, 29(8):1685-1691.
99. Bilensoy E., Sarisozen C., Esendagli G., Dogan A.L., Aktas Y., Sen M., Mungan N.A. Intravesical cationic nanoparticles of chitosan and polycaprolactone for the delivery of mitomycin C to bladder tumors. Int. J. Pharm. 2009, 371:170-176.
100. Jordan J.L., Henderson S., Elson C.M., Zhou J., Kydonieus A., Downie J., Lee T.D.G. Use of a sulfated chitosan derivative to reduce bladder inflammation in the rat. Urology 2007, 70(5):1014-1018.
101. Kim J.H., Kim Y.S., Park K., Lee S., Nam H.Y., Min K.H., Jo H.G., Park J.H., Choi K., Jeong S.Y., Park R.W., Kim I.S., Kim K., Kwon I.C. Antitumor efficacy of cisplatin-loaded glycol chitosan nanoparticles in tumor-bearing mice. J. Control. Release 2008, 127(1):41-49.
102. Saravanakumar G., Min K.H., Min D.S., Kim A.Y., Lee C.M., Cho Y.W., Lee S.C., Kim K., Jeong S.Y., Park K., Park J.H., Kwon I.C. Hydrotropic oligomer-conjugated glycol chitosan as a carrier of paclitaxel: synthesis, characterization, and in vivo biodistribution. J. Control. Release 2009, 140(3):210-217.
103. Ta H.T., Dass C.R., Dunstan D.E. Injectable chitosan hydrogels for localised cancer therapy. J. Control. Release 2008, 126(3):205-216.
104. Tyagi P., Li Z., Chancellor M., De Groat W.C., Yoshimura N., Huang L. Sustained intravesical drug delivery using thermosensitive hydrogel. Pharm. Res. 2004, 21(5):832-837.
105. Bos G.W., Jacobs J.J.L., Koten J.W., Tomme S.V., Veldhuis T., van Nostrum C.F., Otter W.D., Hennink W.E. In situ crosslinked biodegradable hydrogels loaded with IL-2 are effective tools for local IL-2 therapy. Eur. J. Pharm. Sci. 2004, 21:561-567.
106. Yu L., Chang G.T., Zhang H., Ding J.D. Injectable block copolymer hydrogels for sustained release of a PEGylated drug. Int. J. Pharm. 2008, 348(1-2):95-106.
107. Elstad N.L., Fowers K.D. OncoGel (ReGel/paclitaxel) - clinical applications for a novel paclitaxel delivery system. Adv. Drug Deliv. Rev. 2009, 61(10):785-794.
108. Gou M.L., Li X.Y., Dai M., Gong C.Y., Wang X.H., Xie Y., Deng H.X., Chen L.J., Zhao X., Qian Z.Y., Wei Y.Q. A novel injectable local hydrophobic drug delivery system: biodegradable nanoparticles in thermo-sensitive hydrogel. Int. J. Pharm. 2008, 359(1-2):228-233.
109. Colombo R., Salonia A., Da Pozzo L.F., Naspro R., Freschi M., Paroni R., Pavone-Macaluso M., Rigatti P. Combination of intravesical chemotherapy and hyperthermia for the treatment of superficial bladder cancer: preliminary clinical experience. Crit. Rev. Oncol. Hematol. 2003, 47(2):127-139.
110. Gofrit O.N., Shapiro A., Pode D., Sidi A., Nativ O., Leib Z., Witjes J.A., Van Der Heijden A.G., Naspro R., Colombo R. Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer. Urology 2004, 63:466-471.
111. Issels R.D. Hyperthermia adds to chemotherapy. Eur. J. Cancer 2008, 44(17):2546-2554.
112. Horinaga M., Harsch K.M., Fukuyama R., Heston W., Larchian W. Intravesical interleukin-12 gene therapy in an orthotopic bladder cancer model. Urology 2005, 66:461-466.
113. Chancellor M.B., Yoshimura N., Pruchnic R., Huard J. Gene therapy strategies for urological dysfunction. Trends Mol. Med. 2001, 7(7):301-306.
114. Ardelt P., Böhle A. Molecular aspects of bladder cancer IV: gene therapy of bladder cancer. Eur. Urol. 2002, 41(4):372-381.
115. Serikawa T., Kikuchi A., Sugaya S., Suzuki N., Kikuchi H., Tanaka K. In vitro and in vivo evaluation of novel cationic liposomes utilized for cancer gene therapy. J. Control. Release 2006, 113(3):255-260.